IL271558A - חיסון מותאם לפרט - Google Patents

חיסון מותאם לפרט

Info

Publication number
IL271558A
IL271558A IL271558A IL27155819A IL271558A IL 271558 A IL271558 A IL 271558A IL 271558 A IL271558 A IL 271558A IL 27155819 A IL27155819 A IL 27155819A IL 271558 A IL271558 A IL 271558A
Authority
IL
Israel
Prior art keywords
personalized vaccine
personalized
vaccine
Prior art date
Application number
IL271558A
Other languages
English (en)
Other versions
IL271558B2 (he
IL271558B1 (he
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of IL271558A publication Critical patent/IL271558A/he
Publication of IL271558B1 publication Critical patent/IL271558B1/he
Publication of IL271558B2 publication Critical patent/IL271558B2/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24041Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL271558A 2017-06-21 2018-06-21 חיסון מותאם לפרט IL271558B2 (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305760 2017-06-21
EP18305496 2018-04-23
PCT/EP2018/066668 WO2018234506A2 (en) 2017-06-21 2018-06-21 PERSONALIZED VACCINE

Publications (3)

Publication Number Publication Date
IL271558A true IL271558A (he) 2020-02-27
IL271558B1 IL271558B1 (he) 2023-09-01
IL271558B2 IL271558B2 (he) 2024-01-01

Family

ID=62599637

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271558A IL271558B2 (he) 2017-06-21 2018-06-21 חיסון מותאם לפרט

Country Status (10)

Country Link
US (2) US11969462B2 (he)
EP (1) EP3641803A2 (he)
JP (2) JP7334124B2 (he)
KR (2) KR102684237B1 (he)
CN (1) CN111065406A (he)
AU (1) AU2018287159A1 (he)
CA (1) CA3067405A1 (he)
IL (1) IL271558B2 (he)
SG (1) SG11201912429RA (he)
WO (1) WO2018234506A2 (he)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3906045A1 (en) * 2019-01-03 2021-11-10 Evaxion Biotech ApS Vaccines targeting neoepitopes
CN113573729A (zh) 2019-01-10 2021-10-29 詹森生物科技公司 前列腺新抗原及其用途
CN113631185A (zh) * 2019-02-27 2021-11-09 尼克塔治疗公司 用于治疗癌症的免疫治疗组合
IL293051A (he) 2019-11-18 2022-07-01 Janssen Biotech Inc חיסונים המבוססים על מוטנט calr ו- jak2 והשימושים שלהם
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
CN111303277A (zh) * 2020-02-19 2020-06-19 中国人民解放军军事科学院军事医学研究院 一种抗天花病毒免疫球蛋白F(ab′)2及其制备方法
WO2023209068A1 (en) 2022-04-28 2023-11-02 Carbocalyx Gmbh Personalized anticancer vaccine comprising glycoengineered tumour cells or tumour cell fragments
WO2024062098A1 (en) 2022-09-23 2024-03-28 Transgene Recombinant pseudocowpox virus encoding an interleukin-12
CN115927215A (zh) * 2023-01-18 2023-04-07 中国医学科学院病原生物学研究所 一种定向减毒的痘苗病毒疫苗
CN116656730B (zh) * 2023-05-25 2024-03-19 军事科学院军事医学研究院军事兽医研究所 一种表达狂犬病病毒g、m蛋白的重组金丝雀痘病毒及其构建方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
UA82466C2 (uk) 2001-07-18 2008-04-25 Бавариан Нордика А/С Спосіб посилення ампліфікації хордопоксвірусу
US7094412B2 (en) 2001-12-10 2006-08-22 Bavarian Nordic A/S Poxvirus containing formulations and process for preparing stable poxvirus containing compositions
KR101121971B1 (ko) 2003-07-22 2012-03-09 비바리스 부착성 또는 비부착성 조류 세포주를 이용한폭스바이러스의 생산
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
CN101360821A (zh) 2005-11-21 2009-02-04 圣诺菲·帕斯图尔有限公司 重组病毒的稳定制剂
US9024003B2 (en) 2006-01-05 2015-05-05 Transgene S.A. Avian telomerase reverse transcriptase
ES2671230T3 (es) 2006-06-20 2018-06-05 Transgene Sa Procedimiento para producir poxvirus y composiciones de poxvirus
ATE518958T1 (de) 2007-01-30 2011-08-15 Transgene Sa Zur impfung verwendetes papillomavirus-e2- polypeptid
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
AU2008250596C1 (en) 2007-05-14 2010-11-25 Bavarian Nordic A/S Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines
CA2687304A1 (en) 2007-05-15 2008-11-20 Transgene S.A. Signaling peptides
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
JP5421250B2 (ja) 2007-07-03 2014-02-19 トランスジーン ソシエテ アノニム トリ不死化細胞株
CA2705873C (en) 2007-11-19 2012-06-12 Philippe Erbs Poxviral oncolytic vectors
PL2212345T3 (pl) 2007-11-19 2016-07-29 Transgene Sa Onkolityczne wektory pokswirusowe
MX2010008970A (es) 2008-02-12 2011-05-30 Sanofi Pasteur Ltd Metodo que utiliza cromatografia de intercambio ionico y filtracion en gel para la purificacion de poxvirus.
EP2199400A1 (en) 2008-12-22 2010-06-23 Emergent Product Development Germany GmbH Single recombination system and methods of use
RU2560976C2 (ru) 2009-05-12 2015-08-20 Трансген Са Способ продуцирования и очистки ортопоксвируса
CN103180730B (zh) * 2010-05-14 2016-03-02 综合医院公司 鉴定肿瘤特异性新抗原的组合物和方法
NZ730355A (en) 2011-05-24 2022-10-28 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Individualized vaccines for cancer
PL2739293T3 (pl) 2011-08-05 2020-11-16 Sillajen Biotherapeutics, Inc. Sposoby i kompozycje wytwarzania wirusa krowianki
WO2014012051A1 (en) * 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
EP3421613B1 (en) * 2013-03-15 2020-08-19 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
CA2908434C (en) * 2013-04-07 2021-12-28 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
CA2932798C (en) * 2013-12-06 2022-09-20 The Broad Institute, Inc. Formulations for neoplasia vaccines
IL248507B (he) 2014-05-13 2022-07-01 Bavarian Nordic As טיפול משולב לטיפול בסרטן עם פוקוירוס רקומביננטי המבטא אנטיגן שאת ואנטגוניסט או אגוניסט למוליקולת ביקורת חיסונית
JP2017515841A (ja) 2014-05-13 2017-06-15 バヴァリアン・ノルディック・アクティーゼルスカブ 腫瘍抗原を発現するポックスウイルス及びtim−3に対するモノクローナル抗体を用いた癌治療のための併用療法
EP3297660A2 (en) 2015-05-20 2018-03-28 The Broad Institute Inc. Shared neoantigens
KR20180026670A (ko) 2015-05-26 2018-03-13 어드박시스, 인크. 맞춤형 전달 벡터-기반의 면역 요법 및 이의 용도
TW202241500A (zh) * 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
AU2016281958A1 (en) 2015-06-24 2018-02-15 Advaxis, Inc. Manufacturing device and process for personalized delivery vector-based immunotherapy
SG11201804957VA (en) * 2015-12-16 2018-07-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
WO2017177207A1 (en) * 2016-04-07 2017-10-12 Bostongene, Llc Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines

Also Published As

Publication number Publication date
KR20240113607A (ko) 2024-07-22
WO2018234506A2 (en) 2018-12-27
RU2020101489A3 (he) 2021-10-21
US11969462B2 (en) 2024-04-30
JP7334124B2 (ja) 2023-08-28
CA3067405A1 (en) 2018-12-27
IL271558B2 (he) 2024-01-01
KR102684237B1 (ko) 2024-07-11
AU2018287159A1 (en) 2020-01-16
IL271558B1 (he) 2023-09-01
EP3641803A2 (en) 2020-04-29
JP2020530437A (ja) 2020-10-22
US20200138923A1 (en) 2020-05-07
SG11201912429RA (en) 2020-01-30
WO2018234506A3 (en) 2019-03-07
KR20200026894A (ko) 2020-03-11
CN111065406A (zh) 2020-04-24
RU2020101489A (ru) 2021-07-21
US20230277639A1 (en) 2023-09-07
JP2023123609A (ja) 2023-09-05

Similar Documents

Publication Publication Date Title
GB201806688D0 (en) No details
GB201803663D0 (en) No details
GB201801258D0 (en) No details
IL271558A (he) חיסון מותאם לפרט
GB201721011D0 (en) No details
GB201518684D0 (en) Vaccine
GB201801628D0 (en) No details
GB201807647D0 (en) No details
GB201522132D0 (en) Vaccine
GB201616904D0 (en) Vaccine
GB201802344D0 (en) No details
GB201801239D0 (en) No details
GB201710451D0 (en) Comford aid
IL267264A (he) חומרים מסייעים
GB201811353D0 (en) No details
GB201720890D0 (en) No details
GB201709043D0 (en) No details
GB201608821D0 (en) Vaccines
EP3568471A4 (en) PERSONALIZED VACCINES
GB201811382D0 (en) Vaccine
GB201621375D0 (en) Adjuvants
GB201618479D0 (en) Adjuvants
GB201712904D0 (en) Vaccine
GB201704126D0 (en) Vaccine
GB201703809D0 (en) Vaccine